Locoregional recurrence risk
A significant association was observed in studies between the Recurrence Score® result and the risk for locoregional recurrence (LRR), in both node-negative and node-positive patients.1,2 The results of these studies have potential clinical implications for locoregional therapy decisions for patients with node-negative or node-positive ER-positive breast cancer.1-3
The Recurrence Score result in node-negative patients was an independent, significant predictor of LRR along with age and type of initial treatment.
In the node-positive setting, the Recurrence Score result is an independent predictor of LRR along with number of positive nodes and tumor size. These findings may have clinical implications regarding patient selection for postmastectomy chest wall and regional nodal radiation therapy (XRT) and postlumpectomy regional nodal XRT in node-positive, ER-positive patients treated with adjuvant chemoendocrine therapy.
In postmenopausal women with a node-positive, estrogen receptor– or progesterone receptor–positive breast cancer, intermediate or high recurrence score was associated with a significantly increased risk of locoregional recurrence3